Clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) was up 2.33% an hour out from the close following today’s market update.
Management described as encouraging initial data for the second dose cohort of the CLTX CAR T Phase 1 dose escalation study for patients with recurrent/progressive glioblastoma.
The study at US cancer research and treatment facility City of Hope – one of the largest cancer research and treatment organisations in the US - showed an encouraging safety for both the intratumoral and intraventricular methods of application, which were described as generally well tolerated by the cancer patients.
“This preliminary data is encouraging as it demonstrates safety with dual routes of administration, “said Behnam Badie, M.D, Professor and Chief, Division of Neurosurgery; Director, Brain Tumor Program, Department of Surgery, City of Hope.
“We now look forward to advancing the trial to higher dose levels which may provide more therapeutic benefit to patients.”
Initial signal for activity was demonstrated with 2/3 evaluable patients achieving local stability of disease.
As previously disclosed, all patients advanced past the 28-day follow-up without experiencing dose limiting toxicities.
The third dose cohort of the Phase 1 trial is now open to enrolment with dual routes of administration at a total dose of 220 X 106 CLTX CAR T cells.
“We now look forward to advancing the trial to higher dose levels, which may provide more therapeutic benefit to patients,” noted City of Hope Managing Director Behnam Badie.
Chimeric Therapeutics share price has bounced lower over the past three months
Get the latest news and media direct to your inbox